Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 24, 2012, Pages 9623-9628

  Zhang, Xiaolei ^a   Yue, Peibin ^b   Page, Brent D G ^c   Li, Tianshu ^a   Zhao, Wei ^a   Namanja, Andrew T ^d   Paladino, David ^b   Zhao, Jihe ^a   Chen, Yuan ^d   Gunning, Patrick T ^c   Turkson, James ^a,b  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF HAWAII CANCER CENTER   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BP 1 102; CYCLIN D1; FOCAL ADHESION KINASE; GAMMA INTERFERON RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6 RECEPTOR; KRUPPEL LIKE FACTOR; KRUPPEL LIKE FACTOR 8; MIGRATION INHIBITION FACTOR; PAXILLIN; PROTEIN BCL XL; STAT1 PROTEIN; STAT3 PROTEIN; STAT5 PROTEIN; STEROID RECEPTOR COACTIVATOR 1; SURVIVIN; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL GROWTH; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; COMPUTER AIDED DESIGN; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; LUNG CANCER; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; FEMALE; HUMANS; LUNG NEOPLASMS; MICE; STAT3 TRANSCRIPTION FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84862193781     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1121606109     Document Type: Article

References (37)

1. Darnell JE, Jr. (2002) Transcription factors as targets for cancer therapy. Nat Rev Cancer 2:740-749.
2. Yue P, Turkson J (2009) Targeting STAT3 in cancer: How successful are we? Expert Opin Investig Drugs 18(1):45-56.
3. Bromberg J, Darnell JE, Jr. (2000) The role of STATs in transcriptional control and their impact on cellular function. Oncogene 19:2468-2473. (Pubitemid 30339202)
4. Turkson J (2004) STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 8:409-422.
5. Wang T, et al. (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10(1):48-54. (Pubitemid 38524698)
6. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: A leading role for STAT3. Nat Rev Cancer 9:798-809.
7. Grivennikov SI, KarinM(2010) Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 21(1):11-19.
8. Song H, Wang R, Wang S, Lin J (2005) A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc Natl Acad Sci USA 102:4700-4705. (Pubitemid 40471517)
9. Siddiquee K, et al. (2007) Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci USA 104:7391-7396. (Pubitemid 47185916)
10. Gunning PT, et al. (2007) Isoform selective inhibition of STAT1 or STAT3 homo-dimerization via peptidomimetic probes: Structural recognition of STAT SH2 domains. Bioorg Med Chem Lett 17:1875-1878. (Pubitemid 46367686)
11. Turkson J, et al. (2001) Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276:45443-45455.
12. Turkson J, et al. (2004) Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3:261-269. (Pubitemid 39193701)
13. Mandal PK, et al. (2011) Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem 54:3549-3563.
14. Mandal PK, Ren Z, Chen X, Xiong C, McMurray JS (2009) Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3. J Med Chem 52:6126-6141.
15. Chen J, et al. (2010) Structure-based design of conformationally constrained, cell-permeable STAT3 inhibitors. ACS Med Chem Lett 1(2):85-89.
16. Lin L, et al. (2010) Novel STAT3 phosphorylation inhibitors exhibit potent growth-suppressive activity in pancreatic and breast cancer cells. Cancer Res 70:2445-2454.
17. Zhang X, et al. (2010) A novel small-molecule disrupts Stat3 SH2 domain-phosphotyrosine interactions and Stat3-dependent tumor processes. Biochem Pharmacol 79:1398-1409.
18. Dalvit C, et al. (2002) High-throughput NMR-based screening with competition binding experiments. J Am Chem Soc 124:7702-7709. (Pubitemid 34733782)
19. Turkson J, et al. (1999) Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. Mol Cell Biol 19:7519-7528. (Pubitemid 29493415)
20. Turkson J, et al. (1998) Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol 18:2545-2552. (Pubitemid 28183424)
21. Bromberg JF, et al. (1999) Stat3 as an oncogene. Cell 98:295-303. (Pubitemid 29380565)
22. Silver DL, Naora H, Liu J, Cheng W, Montell DJ (2004) Activated signal transducer and activator of transcription (STAT) 3: Localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64:3550-3558. (Pubitemid 38657931)
23. Wang X, Urvalek AM, Liu J, Zhao J (2008) Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells. J BiolChem283:13934-13942.
24. Wang X, et al. (2011) KLF8 promotes human breast cancer cell invasion and metastasis by transcriptional activation of MMP9. Oncogene 30:1901-1911.
25. Nielsen HL, Rønnov-Jessen L, Villadsen R, Petersen OW (2002) Identification of EPSTI1, a novel gene induced by epithelial-stromal interaction in human breast cancer. Genomics 79:703-710. (Pubitemid 34499486)
26. Lee H, et al. (2009) Persistently activated Stat3 maintains constitutive NF-κB activity in tumors. Cancer Cell 15:283-293.
27. Fletcher S, Turkson J, Gunning PT (2008) Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. Chem-MedChem 3:1159-1168.
28. Siddiquee KAZ, et al. (2007) An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability andprocessing and induces antitumor cell effects.ACS ChemBiol 2:787-798. (Pubitemid 351166054)
29. Kim DH, et al. (2006) Anti-inflammatory effects of 8- hydroxydeoxyguanosine in LPS-induced microglia activation: Suppression of STAT3-mediated intercellular adhesion molecule-1 expression. Exp Mol Med 38:417-427. (Pubitemid 44390520)
30. Gho YS, Kim PN, Li HC, Elkin M, Kleinman HK (2001) Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res 61:4253-4257. (Pubitemid 32720996)
31. Jesneck JL, et al. (2009) Do serum biomarkers really measure breast cancer? BMC Cancer 9:164.
32. Abe R, Peng T, Sailors J, Bucala R, Metz CN (2001) Regulation of the CTL response by macrophage migration inhibitory factor. J Immunol 166:747-753. (Pubitemid 32060224)
33. Zubac DP, Wentzel-Larsen T, Seidal T, Bostad L (2010) Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy. BMC Urol 10:20.
34. Hsieh TC, Chiao JW (1995) Growth modulation of human prostatic cancer cells by interleukin-1 and interleukin-1 receptor antagonist. Cancer Lett 95(1-2):119-123.
35. Yamada Y, Karasaki H, Matsushima K, Lee GH, Ogawa K (1999) Expression of an IL-1 receptor antagonist during mouse hepatocarcinogenesis demonstrated by differential display analysis. Lab Invest 79:1059-1067. (Pubitemid 29444536)
36. Oelmann E, et al. (1997) Autocrine interleukin-1 receptor antagonist can support malignant growth of glioblastoma by blocking growth-inhibiting autocrine loop of interleukin-1. Int J Cancer 71:1066-1076. (Pubitemid 27252892)
37. Iizuka N, et al. (1999) Interleukin-1 receptor antagonist mRNA expression and the progression of gastric carcinoma. Cancer Lett 142(2):179-184. (Pubitemid 29304574)